N-acetylcysteine Plus Deferoxamine for Patients With Hypotension
Phase 2
Completed
- Conditions
- Acute Renal FailureHypotension
- Interventions
- Registration Number
- NCT00870883
- Lead Sponsor
- Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
- Brief Summary
Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
- Patients admitted to the ICU
- Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion
Exclusion Criteria
- Age lower than 18 years old
- Chronic renal failure
- A known history of allergy to any of the study drugs
- Using n-acetylcysteine to paracetamol overdose
- Pregnant women
- Patients who used iodinated contrast medium
- Hemoglobin less than 6.5 mg/dl
- Cancer patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description N-acetylcysteine plus deferoxamine N-acetylcysteine and deferoxamine -
- Primary Outcome Measures
Name Time Method Development of acute renal failure 28 days
- Secondary Outcome Measures
Name Time Method 28 day-mortality 28 days Decrease on plasma oxidative damage and inflammatory parameters at the end of drug infusion
Trial Locations
- Locations (1)
São José Hospital
🇧🇷Criciuma, SC, Brazil